Christine Blank
Contributing Editor Christine Blank is a freelance writer based in Florida.
Issues about biosimilar substitution
At a time when biosimilars are of strong interest to insurers and health care systems for cost control, physicians are not rushing to issue a blank check for their substitution. Details here.
Pharmacy prices vary widely for generic heart drugs
The prices of heart failure drugs at retail pharmacies vary widely, and uninsured patients may not be able to afford them, researchers have found.
FDA approves 2 injectable diabetes drugs
Two new diabetes drugs, both long-acting injectable insulin products, were simultaneously approved by FDA.
Novel drug reduces monthly migraine days
A global phase 3 study of erenumab (Amgen and Novartis) showed that the drug was able to prevent migraines headaches.
Multidrug-resistant HIV drug on the horizon
After a successful phase 3 study, a breakthrough therapy to treat multi-drug resistant (MDR) HIV-1 is expected to launch in the United States in 2017.
Bridging the online pharmacy knowledge gap
A majority of pharmacists don’t talk to patients about online pharmacies.
Gilead promises generic versions of new hepatitis drug
After Gilead received FDA approval for a new drug for chronic hepatitis B virus (HBV), it said low-cost, generic versions would also soon be available. That is good news for Gilead, which has been targeted by Congressional representatives for the high cost of Sovaldi and Harvoni hepatitis C treatments.
Breakthrough lymphoma drug on the horizon
FDA granted Breakthrough Therapy Designation to brentuximab vedotin (Adcetris, Seattle Genetics) to treat patients with the most common subtypes of lymphoma.
How Pharmacies are Helping Patients with Diabetes
When pharmacists get involved in patient care, significant improvements are often seen. Diabetes management is one of the most notable examples.
Insulin makers accused of price collusion
U.S. congressmen last week asked the Department of Justice and the Federal Trade Commission to investigate three insulin makers for price collusion—the latest in concerns over insulin prices.